Abstract:1061 Objectives Non-invasively differentiating tumor from inflammation is a long-standing challenge for cancer diagnosis. In clinics, a biopsy or surgery is often required to justify the malignancy of certain types of cancer. Previously, positron emission tomography (PET) with 18F-FDG is the standard non-invasive technique for cancer imaging. However, FDG highlights any tissue with high energy consumption and is not tumor-specific. In addition to accumulating in fast growing tumors, FDG accumulation may be observed in a variety of healthy tissues and ones affected by various non-neoplastic pathologic conditions, such as acute and chronic inflammations and infections. Herein we report a 18F-labeled boron-derived leucine derivative (B-Leu) to distinguish cancer from inflammation in living systems. Methods A boron-derived leucine derivative was synthesized to mimic Leu, of which the transportation depends on L-type amino acid transporter (LAT). 18F-19F isotope exchange reaction was conducted for radiolabeling and quality control was performed by both HPLC and radioTLC. The metabolic stability of 18F-B-Leu was assessed both in vitro and in vivo. PET imaging and bio-distribution studies were performed in mice bearing UM22B xenografts on the right shoulder and inflammation in the left hind limb (Inflammation was introduced by intramuscular injection of turpentine 72 h prior to PET scan). Results The intracellular uptake of B-Leu was highly selective and competed effectively with natural Leu. The cellular uptake of B-Leu increased when incubated with the transfected cells express higher level of LAT-1, and a nearly linear relationship was found between the cellular uptake of Leu and the LAT-1 expression. Remarkably, 18F-B-Leu is highly metabolically stable, which is a unique advantage because metabolism of imaging probe often results in low tumor-specificity with high background uptake. As expected, 18F-B-Leu showed high accumulation in UM22B tumor (12.5 ± 3.1 %ID/g) and low uptake in the rest of the body (liver, 2.23 ± 0.46 %ID/g; muscle, 2.01 ± 0.53 %ID/g; and blood, 1.49 ± 0.82%ID/g). The tracer had predominant renal clearance but with low kidney retention. In addition, representative PET images demonstrated that 18F-B-Leu does not accumulate, but 18F-FDG does accumulate, in the inflammation region. Conclusions A boron-derived Leu derivative was developed and evaluated for targeting LAT-1 expression with PET. Administration of 18F-B-Leu allowed for clear visualization of tumor xenografts in mice, with almost negligible uptake in the inflammatory foci, suggesting a unique advantage over 18F-FDG, which is currently the gold standard PET tracer for clinical diagnosis. Figure: Compared with 11C-Leu and 18F-FDG, 18F-B-Leu showed specific accumulation in the tumor, and notably lower uptake in other major organs and inflammatory lesion.(A), (B) and (C) Whole-body maximum intensity projection PET images of a UM22B bearing mouse showing the uptake of 11C-Leu (A), 18F-B-Leu (B) and 18F-FDG (C). Tumor (t), bladder (b) and inflammation (i) were indicated by white arrows.

Pilot Study of 18F-Bf3-tyr in Healthy Volunteers and Glioma Patients

F-18-Boramino Acid Pet/Ct In Healthy Volunteers And Glioma Patients

18F-Boramino acid PET/CT in healthy volunteers and glioma patients

Metabolic Characteristics of [18f]fluoroboronotyrosine (FBY) PET in Malignant Brain Tumors.

Preclinical evaluation of an 18 F-trifluoroborate methionine derivative for glioma imaging

Biodistribution and radiation dosimetry of D-isomer of 4-borono-2-[18F]fluoro-phenylalanine: A comparative PET/CT study with L-isomer in healthy human volunteers

Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

Preclinical Evaluation Of An F-18-Trifluoroborate Methionine Derivative For Glioma Imaging

A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy

Evaluation of (2S,4S)-4-[18F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging

A bis-boron boramino acid PET tracer for brain tumor diagnosis

A Metabolically Stable Leucine Mimic Identifies Cancer from Inflammation with Positron Emission Tomography

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies

Optimization of Precursor Synthesis Conditions of (2S,4S)4–[18F]FPArg and Its Application in Glioma Imaging

99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression

High folate receptor expression in gliomas can be detected in vivo using folate-based positron emission tomography with high tumor-to-brain uptake ratio divulging potential future targeting possibilities

18F-Trifluoromethylated D-Cysteine as a Promising New PET Tracer for Glioma Imaging: Comparative Analysis With MRI and Histopathology in Orthotopic C6 Models

99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression.